Skip to main content
NVDA+0.14%AAPL+0.02%GOOGL-0.63%MSFT-0.03%AMZN+0.24%TSM-3.01%SPCX-4.19%META-0.23%AVGO-4.35%TSLA-0.03%SKHY-4.35%MU+0.17%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%0700.HK+1.97%ABBV+0.39%CSCO-2.13%1398.HK-1.09%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%1816.HK-26.47%UNH-1.34%3988.HK+1.12%0005.HK+1.71%GE+0.66%HSBA.L-1.95%PM+4.05%0857.HK+0.20%0939.HK+0.75%NFLX+2.68%MS-1.20%HD+3.39%AUDCHF+0.57%EURAUD-0.53%EURCAD-0.50%AUDJPY+0.46%CADCHF+0.45%USDTRY+0.44%GBPTRY+0.41%CADJPY+0.39%USDZAR-0.34%GBPAUD-0.34%GBPHKD+0.32%EURNZD-0.29%AUDUSD+0.29%GBPMXN-0.28%GBPZAR-0.28%GBPCAD-0.27%NZDCHF+0.26%USDCAD-0.25%EURUSD-0.25%AUDNZD+0.23%EURGBP-0.23%EURZAR-0.23%NOKJPY+0.23%PLNJPY+0.21%USDCHF+0.20%NZDCAD-0.20%NZDJPY+0.19%GBPCHF+0.18%SGDJPY+0.18%NZDSGD+0.17%NZDMXN+0.17%USDILS+0.16%AUDSGD+0.16%USDSEK-0.14%USDJPY+0.14%EURJPY-0.13%USDNOK-0.12%USDDKK-0.12%EURHKD+0.11%AUDNOK+0.11%USDPLN-0.10%AUDDKK+0.10%GBPJPY+0.10%USDCNH-0.10%CHFSGD+0.08%GBPNZD-0.07%CHFJPY-0.07%USDMXN-0.07%USDSGD-0.07%USDTHB+0.06%EURCHF-0.06%NZDUSD+0.05%EURSGD+0.05%USDCOP-0.04%EURSEK-0.03%EURCNH+0.03%EURCZK+0.03%CHFNOK+0.02%AUDCAD+0.02%GBPUSD-0.02%EURNOK-0.01%EURPLN+0.01%EURDKK-0.01%USDHKD+0.01%CHFSEK0.00%GBPSGD0.00%XPTUSD+2.03%XAGUSD+1.67%GAGUSD+1.67%HG1+1.38%UKOIL-1.11%XAUUSD+1.09%GAUUSD+1.09%USOIL-0.93%S1+0.68%COTTON+0.49%C1+0.40%XNGUSD+0.30%BTCUSD-1.15%ETHUSD+11.79%USDTUSD-0.04%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-0.91%ZECUSDT-8.44%DOGEUSD+5.25%XMRUSDT-2.55%LINKUSD+7.35%XLMUSD-2.97%BCHUSDT-7.09%LTCUSD+1.20%UNIUSD-7.02%SUIUSD-6.38%HBARUSDT-1.58%TONUSD+18.86%TAOUSDT-6.18%AAVEUSD-4.58%DOTUSDT+2.83%ICPUSDT-6.36%ONDOUSDT+1.64%WLDUSDT-6.00%JUPUSDT-2.55%ARBUSDT-4.90%ATOMUSDT+6.81%STXUSDT+6.42%INJUSDT-6.70%FETUSDT-4.17%PYTHUSDT+9.49%TIAUSDT+9.52%SEIUSDT-3.41%IMXUSDT+7.40%GRTUSDT-3.61%OPUSDT-0.41%WIFUSDT-8.72%IOTAUSDT-5.65%AXSUSDT-5.63%POLUSDT-2.65%FARTCOINUSDT+1.82%EOSUSDT-0.69%DYDXUSDT-0.24%GALAUSDT-4.26%ORDIUSDT-6.31%RONINUSDT-4.25%NOTUSDT-5.84%NVDA+0.14%AAPL+0.02%GOOGL-0.63%MSFT-0.03%AMZN+0.24%TSM-3.01%SPCX-4.19%META-0.23%AVGO-4.35%TSLA-0.03%SKHY-4.35%MU+0.17%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%0700.HK+1.97%ABBV+0.39%CSCO-2.13%1398.HK-1.09%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%1816.HK-26.47%UNH-1.34%3988.HK+1.12%0005.HK+1.71%GE+0.66%HSBA.L-1.95%PM+4.05%0857.HK+0.20%0939.HK+0.75%NFLX+2.68%MS-1.20%HD+3.39%AUDCHF+0.57%EURAUD-0.53%EURCAD-0.50%AUDJPY+0.46%CADCHF+0.45%USDTRY+0.44%GBPTRY+0.41%CADJPY+0.39%USDZAR-0.34%GBPAUD-0.34%GBPHKD+0.32%EURNZD-0.29%AUDUSD+0.29%GBPMXN-0.28%GBPZAR-0.28%GBPCAD-0.27%NZDCHF+0.26%USDCAD-0.25%EURUSD-0.25%AUDNZD+0.23%EURGBP-0.23%EURZAR-0.23%NOKJPY+0.23%PLNJPY+0.21%USDCHF+0.20%NZDCAD-0.20%NZDJPY+0.19%GBPCHF+0.18%SGDJPY+0.18%NZDSGD+0.17%NZDMXN+0.17%USDILS+0.16%AUDSGD+0.16%USDSEK-0.14%USDJPY+0.14%EURJPY-0.13%USDNOK-0.12%USDDKK-0.12%EURHKD+0.11%AUDNOK+0.11%USDPLN-0.10%AUDDKK+0.10%GBPJPY+0.10%USDCNH-0.10%CHFSGD+0.08%GBPNZD-0.07%CHFJPY-0.07%USDMXN-0.07%USDSGD-0.07%USDTHB+0.06%EURCHF-0.06%NZDUSD+0.05%EURSGD+0.05%USDCOP-0.04%EURSEK-0.03%EURCNH+0.03%EURCZK+0.03%CHFNOK+0.02%AUDCAD+0.02%GBPUSD-0.02%EURNOK-0.01%EURPLN+0.01%EURDKK-0.01%USDHKD+0.01%CHFSEK0.00%GBPSGD0.00%XPTUSD+2.03%XAGUSD+1.67%GAGUSD+1.67%HG1+1.38%UKOIL-1.11%XAUUSD+1.09%GAUUSD+1.09%USOIL-0.93%S1+0.68%COTTON+0.49%C1+0.40%XNGUSD+0.30%BTCUSD-1.15%ETHUSD+11.79%USDTUSD-0.04%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-0.91%ZECUSDT-8.44%DOGEUSD+5.25%XMRUSDT-2.55%LINKUSD+7.35%XLMUSD-2.97%BCHUSDT-7.09%LTCUSD+1.20%UNIUSD-7.02%SUIUSD-6.38%HBARUSDT-1.58%TONUSD+18.86%TAOUSDT-6.18%AAVEUSD-4.58%DOTUSDT+2.83%ICPUSDT-6.36%ONDOUSDT+1.64%WLDUSDT-6.00%JUPUSDT-2.55%ARBUSDT-4.90%ATOMUSDT+6.81%STXUSDT+6.42%INJUSDT-6.70%FETUSDT-4.17%PYTHUSDT+9.49%TIAUSDT+9.52%SEIUSDT-3.41%IMXUSDT+7.40%GRTUSDT-3.61%OPUSDT-0.41%WIFUSDT-8.72%IOTAUSDT-5.65%AXSUSDT-5.63%POLUSDT-2.65%FARTCOINUSDT+1.82%EOSUSDT-0.69%DYDXUSDT-0.24%GALAUSDT-4.26%ORDIUSDT-6.31%RONINUSDT-4.25%NOTUSDT-5.84%
PB

Pacific Biosciences of California, Inc. (PACB)

NASDAQ • Healthcare

$2.29
-$0.42 (-15.4%)
Market closed

Last close at October 8, 2026 at 20:00 UTC

Open$2.63
Day Range$2.22 - $2.69
Avg. Volume (3M)17.8M
Market Cap$714.3M
52 Week Range
$1.07$3.44
Next EarningsIn 25 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$39M100%
Gross Profitminus cost of goods$12.6M32%

Fundamentals & Financials

Revenue (TTM)
$159.2M
Net Income (TTM)
-$131.3M
EPS (TTM)
-$0.43
ROA (TTM)
-17.48%
Current Ratio
4.92

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+36.8%Q1 2026-$0.12
+82.4%Q2 2026-$0.03
-9.4%Q3 2026-$0.14
Next

Nov 3

in 25 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -9.4%

Pacific Biosciences’ second fiscal quarter of 2026 results missed consensus on both revenue and EPS, as reported August 3, 2026, with revenue down ~2% year over year to about $39.0 million. The company posted EPS of -$0.14, down ~8% from -$0.13 a year ago, and it trailed the -$0.13 estimate by $0.01, while revenue of $39.0 million trailed the $42.9 million estimate (-9.1%). Profitability remained pressured, with gross profit of roughly $12.6 million translating to a gross margin of about 32.4%, and operating income of about -$44.6 million implying an operating margin near -114.4%. Net income was about -$44.7 million, down ~7% from roughly -$41.9 million in the year-ago quarter. Consensus for the next period calls for EPS of -$0.13 on revenue of $43.8 million.

Next report — what to expect

Pacific Biosciences of California, Inc. (PACB) reports on November 3, 2026. For the upcoming quarter, consensus calls for EPS of -$0.126 on revenue of $43.8 million. As trailing context, revenue fell -1.9% year over year last quarter. PACB has beaten EPS in 4 of 8 most recent quarters.

View full earnings history

About Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. (NASDAQ: PACB) makes genetic sequencing instruments and related consumables for the medical technology market. Its PacBio Sequencing Systems sit at the center of the business, which generated $160.0 million in FY2025 revenue. The company was founded in 2000 and is based in Menlo Park, California.

Name
Pacific Biosciences of California, Inc.
CEO
Mark Van Oene
Website
www.pacb.com
Industry
Healthcare
Year Founded
2000
Employees
485

Today's Snapshot

AI-generated

PACB closed 15.4% below yesterday's close, while its sector was flat. Barclays, an investment bank, maintained its recommendation to sell Pacific Biosciences shares.

Trading Volume

Below 10d avg (30.8M)

21.8M

vs S&P 500 Today

Strong Underperformance

-14.90%

Updated: October 8, 2026 at 20:12 UTC

PACB Headlines

Healthcare stocks fall after weak US jobs data

March 6, 2026

3 min read
View All News

Technical Indicators

5 Buy2 Neutral1 Sell
PACB exhibits a strong buy profile built on robust trend strength and heavy accumulation. ADX points to a pronounced trend, multiple medium- and long-term moving averages sit below the market, and MACD and momentum readings are constructive, while on-balance volume shows strong buying interest. Notably, the short-term average is close to the price and the classic pivot resides above current levels, suggesting near-term resistance, and ATR is elevated, indicating higher volatility; money flow appears extended. Technical takeaway: Strong buy — trend and volume support prevail, but elevated volatility and MFI suggest caution.
All signals
  • EMA (5 indicators)$1.58 - $2.32
    Buy
  • RSI (14)61.78
    Neutral
  • Stochastic %K (14, 3, 3)58.73
    Neutral
  • MACD Level (12, 26)0.34
    Buy

Peers & Related Assets

ILMNIllumina, Inc.
$264.57-1.2%
QSIQuantum-Si incorporated
$1.22-4.7%
BNGOBionano Genomics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.